BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19836370)

  • 1. Searching for new animal models of Alzheimer's disease.
    Epis R; Gardoni F; Marcello E; Genazzani A; Canonico PL; Di Luca M
    Eur J Pharmacol; 2010 Jan; 626(1):57-63. PubMed ID: 19836370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic mouse models of Alzheimer's disease: phenotype and application.
    Higgins GA; Jacobsen H
    Behav Pharmacol; 2003 Sep; 14(5-6):419-38. PubMed ID: 14501255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key?
    Walker LC; Bian F; Callahan MJ; Lipinski WJ; Durham RA; LeVine H
    Amino Acids; 2002; 23(1-3):87-93. PubMed ID: 12373522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy.
    Götz J; Streffer JR; David D; Schild A; Hoerndli F; Pennanen L; Kurosinski P; Chen F
    Mol Psychiatry; 2004 Jul; 9(7):664-83. PubMed ID: 15052274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.
    Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M
    Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
    Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
    J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of amyloid-beta-related pathologies in Alzheimer's disease.
    Philipson O; Lord A; Gumucio A; O'Callaghan P; Lannfelt L; Nilsson LN
    FEBS J; 2010 Mar; 277(6):1389-409. PubMed ID: 20136653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of modeling Alzheimer's disease in transgenic mice.
    McGowan E; Eriksen J; Hutton M
    Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anatomical and functional phenotyping of mice models of Alzheimer's disease by MR microscopy.
    Benveniste H; Ma Y; Dhawan J; Gifford A; Smith SD; Feinstein I; Du C; Grant SC; Hof PR
    Ann N Y Acad Sci; 2007 Feb; 1097():12-29. PubMed ID: 17413006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.
    Morgan D; Diamond DM; Gottschall PE; Ugen KE; Dickey C; Hardy J; Duff K; Jantzen P; DiCarlo G; Wilcock D; Connor K; Hatcher J; Hope C; Gordon M; Arendash GW
    Nature; 2000 Dec 21-28; 408(6815):982-5. PubMed ID: 11140686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What transgenic mice tell us about neurodegenerative disease.
    Gurney ME
    Bioessays; 2000 Mar; 22(3):297-304. PubMed ID: 10684590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.
    Pihlaja R; Koistinaho J; Malm T; Sikkilä H; Vainio S; Koistinaho M
    Glia; 2008 Jan; 56(2):154-63. PubMed ID: 18004725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease.
    Ognibene E; Middei S; Daniele S; Adriani W; Ghirardi O; Caprioli A; Laviola G
    Behav Brain Res; 2005 Jan; 156(2):225-32. PubMed ID: 15582108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
    He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
    Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: Abeta, tau and synaptic dysfunction.
    LaFerla FM; Oddo S
    Trends Mol Med; 2005 Apr; 11(4):170-6. PubMed ID: 15823755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice.
    Hanna A; Horne P; Yager D; Eckman C; Eckman E; Janus C
    Genes Brain Behav; 2009 Oct; 8(7):676-84. PubMed ID: 19531156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease.
    Lee GD; Aruna JH; Barrett PM; Lei DL; Ingram DK; Mouton PR
    Brain Res Bull; 2005 Apr; 65(4):317-22. PubMed ID: 15811597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
    Götz J; Ittner LM; Kins S
    J Neurochem; 2006 Aug; 98(4):993-1006. PubMed ID: 16787410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
    Janus C; Pearson J; McLaurin J; Mathews PM; Jiang Y; Schmidt SD; Chishti MA; Horne P; Heslin D; French J; Mount HT; Nixon RA; Mercken M; Bergeron C; Fraser PE; St George-Hyslop P; Westaway D
    Nature; 2000 Dec 21-28; 408(6815):979-82. PubMed ID: 11140685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.